Search research articles
Contact Us
Filters
Showing results (61-70 of 390) with videos related to
Page
of 39
Sort By:
Antimicrobial Agents and Chemotherapy
|
October 23, 1997
Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses
S C Chien, M C Rogge, L G Gisclon, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 16, 2016
Comparison of Planning Quality and Efficiency Between Conventional and Knowledge-based Algorithms in Nasopharyngeal Cancer Patients Using Intensity Modulated Radiation Therapy
Amy T Y Chang, Albert W M Hung, Fion W K Cheung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 13, 2023
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax
Nitin Jain, Lisa J Croner, John N Allan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2023
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
Jennifer A Woyach, Paolo Ghia, John C Byrd, et al.
Leukemia & Lymphoma
|
January 11, 2022
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies
Jan A Burger, Tadeusz Robak, Fatih Demirkan, et al.
Molecular Cancer Therapeutics
|
April 22, 2017
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Hsu-Ping Kuo, Scott A Ezell, Karl J Schweighofer, et al.
Annals of Hematology
|
May 21, 2021
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study
Richard Greil, Alessandra Tedeschi, Carol Moreno, et al.
Blood Advances
|
November 23, 2020
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis
Ariela Noy, Sven de Vos, Morton Coleman, et al.
Physical Review Letters
|
January 22, 2002
Search for CP violation in the decays D+--> K(S)pi+ and D+-->K(S)K+
J M Link, M Reyes, P M Yager, et al.
Physical Review Letters
|
April 17, 2002
A high statistics measurement of the Lambda(+)(c) lifetime
J M Link, M Reyes, P M Yager, et al.
Page
of 39
Search research articles
Search
Showing results (61-70 of 390) with videos related to
Sort By:
Page
of 39
Antimicrobial Agents and Chemotherapy
|
October 23, 1997
Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses
S C Chien, M C Rogge, L G Gisclon, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 16, 2016
Comparison of Planning Quality and Efficiency Between Conventional and Knowledge-based Algorithms in Nasopharyngeal Cancer Patients Using Intensity Modulated Radiation Therapy
Amy T Y Chang, Albert W M Hung, Fion W K Cheung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 13, 2023
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax
Nitin Jain, Lisa J Croner, John N Allan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2023
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
Jennifer A Woyach, Paolo Ghia, John C Byrd, et al.
Leukemia & Lymphoma
|
January 11, 2022
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies
Jan A Burger, Tadeusz Robak, Fatih Demirkan, et al.
Molecular Cancer Therapeutics
|
April 22, 2017
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Hsu-Ping Kuo, Scott A Ezell, Karl J Schweighofer, et al.
Annals of Hematology
|
May 21, 2021
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study
Richard Greil, Alessandra Tedeschi, Carol Moreno, et al.
Blood Advances
|
November 23, 2020
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis
Ariela Noy, Sven de Vos, Morton Coleman, et al.
Physical Review Letters
|
January 22, 2002
Search for CP violation in the decays D+--> K(S)pi+ and D+-->K(S)K+
J M Link, M Reyes, P M Yager, et al.
Physical Review Letters
|
April 17, 2002
A high statistics measurement of the Lambda(+)(c) lifetime
J M Link, M Reyes, P M Yager, et al.
Page
of 39